What do systematic reviews say?

PERPHENAZINE vs antipsychotics

It is very uncertain whether PERPHENAZINE changes other adverse events: any serious adverse event ‐ short and long term compared with ANY ANTIPSYCHOTICS (very low certainty).

• Perphenazine for schizophrenia 2015 · Cochrane Headline outcomes only
  RR 0.98 [0.68, 1.41]
  2 studies · 1760 participants
  Very low

RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE)

RISPERIDONE DEPOT showed no clear difference in adverse events: Any prolactin‐related ‐ medium term compared with ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE) (moderate certainty).

• Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
  RR 1.02 [0.61, 1.71]
  2 studies · 1666 participants
  Moderate

RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE)

RISPERIDONE DEPOT showed no clear difference in adverse events: Any glucose‐related ‐ medium/long term compared with ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE) (low certainty).

• Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
  RR 1.79 [0.89, 3.61]
  3 studies · 2413 participants
  Low

RISPERIDONE DEPOT vs GENERAL ORAL ANTIPSYCHOTICS

• Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported